keyword
https://read.qxmd.com/read/38667995/prophylactic-use-of-pentoxifylline-and-tocopherol-for-prevention-of-osteoradionecrosis-of-the-jaw-after-dental-extraction-in-post-radiated-oral-and-oropharyngeal-cancer-patients-an-initial-case-series
#41
JOURNAL ARTICLE
Adepitan A Owosho, Katherine A DeColibus, Osariemen Okhuaihesuyi, Layne C Levy
Osteoradionecrosis of the jaw is a morbid complication of radiotherapy in patients with oral and oropharyngeal cancers that may be precipitated by dental extractions. Pentoxifylline and tocopherol (PENTO) has been utilized in the management of osteoradionecrosis and as prophylaxis for post-radiated head and neck oncology patients requiring an invasive dental procedure. This observational study aims to report the outcome of the prophylactic use of PENTO in the prevention of osteoradionecrosis of the jaw after dental extractions in post-radiated oral and oropharyngeal cancer patients and to review the current literature on this topic...
March 22, 2024: Dentistry Journal
https://read.qxmd.com/read/38667524/sexual-functioning-and-impact-on-quality-of-life-in-patients-with-early-onset-colorectal-cancer-a-systematic-review
#42
REVIEW
Catalin Vladut Ionut Feier, Ionut Andrei Paunescu, Alaviana Monique Faur, Gabriel Veniamin Cozma, Andiana Roxana Blidari, Calin Muntean
This systematic review investigates the intersection of early-onset colorectal cancer (EOCRC), sexual functioning, and associated quality of life (QoL), aiming to understand the comprehensive impact of EOCRC on these critical dimensions. Through an extensive search across PubMed, Scopus, and Embase up until November 2023, this study synthesized evidence from the literature while adhering to PRISMA guidelines. The studies included EOCRC patients under 50 years, which examined sexual functioning and QoL using validated instruments, and were published in English...
March 26, 2024: Diseases (Basel)
https://read.qxmd.com/read/38667342/utilization-of-clinical-practice-guidelines-for-cancer-care-in-routine-practice-and-during-the-coronavirus-disease-2019-pandemic-in-india
#43
JOURNAL ARTICLE
Prashant Mathur, Thilagavathi Ramamoorthy, Sudarshan Kondalli Lakshminarayana, Anita Nath, Stany Mathew, Gurpreet Kaur Rajput
AIM: The coronavirus disease 2019 (COVID-19) pandemic affected cancer service delivery and the feasibility of following the standard treatment guidelines. The present paper describes the use of clinical care guidelines for cancer management in routine practice and the approach adopted towards cancer care during the COVID-19 pandemic in India. METHODS: A web-based survey was done in 107 hospitals (including public and private health facilities) that hosted Hospital-Based Cancer Registries under the National Cancer Registry Programme...
April 26, 2024: Asia-Pacific Journal of Clinical Oncology
https://read.qxmd.com/read/38666473/radiation-oncologists-views-on-adjuvant-radiotherapy-for-early-stage-breast-cancer-in-the-elderly-comparisons-between-japan-and-the-united-states
#44
JOURNAL ARTICLE
Yoshiki Kuwatsuru, Anneyuko I Saito, Keisuke Usui
PURPOSE: To understand perspective on breast cancer using a survey. MATERIALS & METHODS: Questionnaire was distributed to 304 Japanese radiation oncologists (RadOncs) (response rate: 64.1%). Result was compared with a similar US survey. RESULTS: In a scenario with an 81-year-old patient with comorbidities, while most US RadOncs chose to tell that radiation might not be necessary, 2% of Japanese chose it. In a scenario with a healthy 65-year-old breast cancer patient with lumpectomy, while most US RadOncs chose to discuss omission of radiation, 24...
April 26, 2024: Cancer Investigation
https://read.qxmd.com/read/38666471/-ttn-mutation-in-endometrial-endometrioid-carcinoma-is-associated-with-poor-clinical-outcomes-and-high-tumor-mutation-burden
#45
JOURNAL ARTICLE
Lihong Li, Pinli Yue, Jiarun Zhu, Luyuan Li, Kaipeng Wang, Guangwen Yuan, Yan Song
Endometrioid endometrial carcinoma (EEC) stands as a prevalent gynecologic malignancy in developed regions. However, predicting relapse cases remains challenging, necessitating the identification of a novel biomarker for EEC relapse. The assessment of tumor mutational burden (TMB) is pivotal for immunotherapy in EEC patients. However, both whole-exome sequencing (WES) and targeted sequencing encountered application-related difficulties. In light of this, standardized and simplified techniques for TMB measurement are imperative...
April 26, 2024: Cancer Investigation
https://read.qxmd.com/read/38665954/impact-of-neoadjuvant-relugolix-on-patient-reported-sexual-function-and-bother
#46
JOURNAL ARTICLE
Jessica Y Hsueh, Lindsey Gallagher, Min Ji Koh, Shaine Eden, Sarthak Shah, Markus Wells, Malika Danner, Alan Zwart, Marilyn Ayoob, Deepak Kumar, Paul Leger, Nancy A Dawson, Simeng Suy, Rachel Rubin, Sean P Collins
INTRODUCTION: Sexual function following local treatment for prostate cancer is an important quality of life concern. Relugolix is a novel oral GnRH receptor antagonist used in combination with radiation therapy in the treatment of unfavorable prostate cancer. It has been shown to achieve rapid and profound testosterone suppression. As a result, these very low testosterone levels may impact both sexual functioning and perceptions. This prospective study sought to assess neoadjuvant relugolix-induced sexual dysfunction prior to stereotactic body radiation therapy (SBRT)...
2024: Frontiers in Oncology
https://read.qxmd.com/read/38665884/exploring-patient-perspectives-on-electronic-patient-reported-outcome-measures-in-home-based-cancer-palliative-care-a-qualitative-study
#47
JOURNAL ARTICLE
Letteria Consolo, Ilaria Basile, Stella Colombo, Daniele Rusconi, Loredana Pasquot, Tiziana Campa, Augusto Caraceni, Maura Lusignani
BACKGROUND: Electronic patient-reported outcomes (ePROMs) enhance symptom management and patients' engagement in palliative cancer care. However, integrating them into this setting brings challenges, including patients' familiarity with technological devices and declining health status. Prioritizing the patient's acceptability and feasibility is crucial for their adoption. However, more knowledge is needed about patients' perspectives on the adoption of ePROMs in the community, especially for home-based palliative care...
2024: Digital Health
https://read.qxmd.com/read/38665845/improving-olaparib-exposure-to-optimize-adverse-effects-management
#48
JOURNAL ARTICLE
Marylise Sterlé, Alicja Puszkiel, Chloé Burlot, Eva Pereira, Audrey Bellesoeur, Sixtine De Percin, Guillaume Beinse, Jean-David Fumet, Laure Favier, Julie Niogret, Benoit Blanchet, Bernard Royer, Leïla Bengrine-Lefevre, Antonin Schmitt
BACKGROUND: Olaparib is an inhibitor of the human poly-(ADP-ribose)-polymerase enzymes (PARP1/2) needed to repair single-strand DNA breaks. It is used in breast, ovarian, prostate and pancreatic cancer. OBJECTIVES: This work aimed to describe the pharmacokinetics/pharmacodynamics (PK/PD) relationship between olaparib plasma concentrations and common adverse effects (i.e. anaemia and hypercreatininaemia), in a real-life setting, to propose a target concentration for therapeutic drug monitoring...
2024: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/38665754/cyclophosphamide-bortezomib-and-dexamethasone-and-severe-systolic-heart-failure-a-case-report
#49
Sagar Pandey, Ernestine Faye S Tan, Amulya Bellamkonda, Binit Aryal, Madhumati Kalavar
Multiple myeloma (MM) is a neoplastic proliferation of plasma cells in bone marrow. Pharmacotherapy for the management of patients with MM includes drug classes like proteasome inhibitors, monoclonal antibodies, immunomodulators, alkylating agents, steroids, etc. We present a case of new-onset heart failure with reduced ejection fraction (HFrEF) in a patient with previously normal ejection fraction after treatment with a cyclophosphamide, bortezomib, and dexamethasone (CyBorD) chemotherapeutic regimen. An echocardiogram done after the completion of nine cycles of chemotherapy in a period of about 4...
March 2024: Curēus
https://read.qxmd.com/read/38665637/financial-toxicity-and-its-risk-factors-among-patients-with-cancer-in-china-a-nationwide-multisite-study
#50
JOURNAL ARTICLE
Binbin Xu, Winnie K W So, Kai Chow Choi, Yu Huang, Mei Liu, Lanxiang Qiu, Jianghong Tan, Hua Tao, Keli Yan, Fei Yang
OBJECTIVE: We assessed financial toxicity (FT) among Chinese patients with cancer and investigated associated risk factors guided by a multilevel conceptual framework. METHODS: Applying multistage stratified sampling, we selected six tertiary and six secondary hospitals across three economically diverse provinces in China. From February to October 2022, 1208 patients with cancer participated. FT was measured using the COmprehensive Score for financial Toxicity (COST), with 28 potential risk factors identified at multilevel...
May 2024: Asia-Pacific Journal of Oncology Nursing
https://read.qxmd.com/read/38665312/a-new-sarcoma-shortly-after-treatment-for-high-grade-glioma-with-adjuvant-chemoradiation-a-case-report
#51
Abdossalam M Madkhali, Hasah F Alaluan, Mohammed H Alnajeim, Eyad F Al Saeed, Abdulrazag M Ajlan, Ahmed Abdelwarith, Ali Abduh, Saleh Albanyan, Ashwag Alqurashi, Hisham Alkhalidi
INTRODUCTION: High-grade gliomas are central nervous system tumors conventionally treated with surgery followed by adjuvant chemoradiotherapy. Secondary cancer due to radiation therapy is a rare yet established phenomenon that typically occurs years after radiation therapy. CASE PRESENTATION: In this case, we discuss an early presentation of a second cancer adjacent to the radiation field. This case report is of a 52-year-old male who developed a new scalp sarcoma at the site of primary surgery 8 months after radiation therapy...
2024: Case Reports in Oncology
https://read.qxmd.com/read/38665130/investigation-of-polypharmacy-antimicrobial-related-potential-drug-drug-interactions-in-patients-with-hematological-malignancies
#52
JOURNAL ARTICLE
Zeynep Oktay, Rahmet Güner, Bircan Kayaaslan, İmran Hasanoğlu, Ayşe Kaya Kalem, Gülsüm Özet
PURPOSE: Drug-drug interactions (DDIs) occur when one drug interferes with the pharmacological activity of another and can lead to increased side effects. The purpose of this study was to examine potential interactions between antimicrobials and other drugs in patients with hematological malignancies (HMs). METHOD: The medications used by 233 patients with HMs before and during hospitalization in Ankara City Hospital Hematology Clinic services between January 2021 and July 2021 were examined...
April 26, 2024: Journal of Oncology Pharmacy Practice
https://read.qxmd.com/read/38664776/impact-of-resection-margin-on-outcome-in-soft-tissue-sarcomas-of-the-extremities-treated-with-limb-sparing-surgery-and-postoperative-radiotherapy
#53
JOURNAL ARTICLE
Chun-Chieh Chen, Yao-Yu Wu, Jo-Ting Kao, Chih-Hsiang Chang, Shih-Chiang Huang, Hsin-Nung Shih
BACKGROUND: The standard curative treatments for extremity soft tissue sarcoma (ESTS) include surgical resection with negative margins and perioperative radiotherapy. However, the optimal resection margin remains controversial. This study aimed to evaluate the outcomes in ESTS between microscopically positive margin (R1) and microscopically negative margin (R0) according to the Union for International Cancer Control (UICC) (R + 1 mm) classification. METHODS: Medical records of patients with localized ESTS who underwent primary limb-sparing surgery and postoperative radiotherapy between 2004 and 2015 were retrospectively reviewed...
April 26, 2024: World Journal of Surgical Oncology
https://read.qxmd.com/read/38664705/pan-cancer-analysis-implicates-novel-insights-of-lactate-metabolism-into-immunotherapy-response-prediction-and-survival-prognostication
#54
JOURNAL ARTICLE
Dongjie Chen, Pengyi Liu, Xiongxiong Lu, Jingfeng Li, Debin Qi, Longjun Zang, Jiayu Lin, Yihao Liu, Shuyu Zhai, Da Fu, Yuanchi Weng, Hongzhe Li, Baiyong Shen
BACKGROUND: Immunotherapy has emerged as a potent clinical approach for cancer treatment, but only subsets of cancer patients can benefit from it. Targeting lactate metabolism (LM) in tumor cells as a method to potentiate anti-tumor immune responses represents a promising therapeutic strategy. METHODS: Public single-cell RNA-Seq (scRNA-seq) cohorts collected from patients who received immunotherapy were systematically gathered and scrutinized to delineate the association between LM and the immunotherapy response...
April 25, 2024: Journal of Experimental & Clinical Cancer Research: CR
https://read.qxmd.com/read/38664630/a-qualitative-evaluation-of-factors-influencing-tumor-treating-fields-ttfields-therapy-decision-making-among-brain-tumor-patients-and-physicians
#55
JOURNAL ARTICLE
Priya Kumthekar, Madison Lyleroehr, Leilani Lacson, Rimas V Lukas, Karan Dixit, Roger Stupp, Timothy Kruser, Jeff Raizer, Alexander Hou, Sean Sachdev, Margaret Schwartz, Jessica Bajas Pa, Ray Lezon, Karyn Schmidt, Christina Amidei, Karen Kaiser
BACKGROUND: Tumor Treating Fields (TTFields) Therapy is an FDA-approved therapy in the first line and recurrent setting for glioblastoma. Despite Phase 3 evidence showing improved survival with TTFields, it is not uniformly utilized. We aimed to examine patient and clinician views of TTFields and factors shaping utilization of TTFields through a unique research partnership with medical neuro oncology and medical social sciences. METHODS: Adult glioblastoma patients who were offered TTFields at a tertiary care academic hospital were invited to participate in a semi-structured interview about their decision to use or not use TTFields...
April 25, 2024: BMC Cancer
https://read.qxmd.com/read/38664020/mri-and-18-f-fet-pet-for-multimodal-treatment-monitoring-in-patients-with-brain-metastases-a-cost-effectiveness-analysis
#56
JOURNAL ARTICLE
Jurij Rosen, Jan-Michael Werner, Garry S Ceccon, Elena K Rosen, Michael M Wollring, Isabelle Stetter, Philipp Lohmann, Felix M Mottaghy, Gereon R Fink, Karl-Josef Langen, Norbert Galldiks
PET using the radiolabeled amino acid O -(2-[18 F]fluoroethyl)-l-tyrosine (18 F-FET) has been shown to be of value for treatment monitoring in patients with brain metastases after multimodal therapy, especially in clinical situations with equivocal MRI findings. As medical procedures must be justified socioeconomically, we determined the effectiveness and cost-effectiveness of 18 F-FET PET for treatment monitoring of multimodal therapy, including checkpoint inhibitors, targeted therapies, radiotherapy, and combinations thereof in patients with brain metastases secondary to melanoma or non-small cell lung cancer...
April 25, 2024: Journal of Nuclear Medicine
https://read.qxmd.com/read/38663582/patient-reported-outcomes-after-personalised-dose-escalation-for-stage-ii-iii-non-small-cell-lung-cancer-patients-results-from-the-randomised-artforce-pet-boost-trial
#57
JOURNAL ARTICLE
Saskia A Cooke, José S A Belderbos, Bart Reymen, Maarten Lambrecht, Gitte Fredberg Persson, Corinne Faivre-Finn, Edith M T Dieleman, Judi N A van Diessen, Jan-Jakob Sonke, Dirk de Ruysscher
BACKGROUND AND PURPOSE: The ultimate challenge in dose-escalation trials lies in finding the balance between benefit and toxicity. We examined patient-reported outcomes (PROs), including health-related quality of life (HRQoL) in patients with locally advanced non-small cell lung cancer (LA-NSCLC), treated with dose-escalated radiotherapy. MATERIALS AND METHODS: The international, randomised, phase 2 ARTFORCE PET-Boost study (NCT01024829) aimed to improve 1-year freedom from local failure rates in patients with stage II-III NSCLC, with a ≥ 4 cm primary tumour...
April 23, 2024: Radiotherapy and Oncology
https://read.qxmd.com/read/38663531/understanding-breast-cancer-patient-pathways-and-their-impact-on-survival-in-mexico
#58
JOURNAL ARTICLE
Fatin Izzati Ramli, Praveen Thokala, Thaison Tong, Karla Unger-Saldaña
BACKGROUND: Understanding patient pathways from discovery of breast symptoms to treatment start can aid in identifying ways to improve access to timely cancer care. This study aimed to describe the patient pathways experienced by uninsured women from detection to treatment initiation for breast cancer in Mexico City and estimate the potential impact of earlier treatment on patient survival. METHODS: We used process mining, a data analytics technique, to create maps of the patient pathways...
April 23, 2024: Journal of Cancer Policy
https://read.qxmd.com/read/38663007/digital-therapeutic-mika-targeting-distress-in-patients-with-cancer-results-from-a-nationwide-waitlist-randomized-controlled-trial
#59
RANDOMIZED CONTROLLED TRIAL
Franziska Springer, Ayline Maier, Michael Friedrich, Jan Simon Raue, Gandolf Finke, Florian Lordick, Guy Montgomery, Peter Esser, Hannah Brock, Anja Mehnert-Theuerkauf
BACKGROUND: Distress is highly prevalent among patients with cancer, but supportive care needs often go unmet. Digital therapeutics hold the potential to overcome barriers in cancer care and improve health outcomes. OBJECTIVE: This study conducted a randomized controlled trial to investigate the efficacy of Mika, an app-based digital therapeutic designed to reduce distress across the cancer trajectory. METHODS: This nationwide waitlist randomized controlled trial in Germany enrolled patients with cancer across all tumor entities diagnosed within the last 5 years...
April 25, 2024: Journal of Medical Internet Research
https://read.qxmd.com/read/38662980/toward-equitable-precision-oncology-monitoring-racial-and-ethnic-inclusion-in-genomics-and-clinical-trials
#60
JOURNAL ARTICLE
Jennyfer M García-Cárdenas, Alberto Indacochea, David Pesantez-Coronel, Martín Terán-Navas, Ana Aleaga, Isaac Armendáriz-Castillo, Lizbeth Peña Zúñiga, Carla Morán-Erazo, Erik Chávez-Vélez, Andy Pérez-Villa, Andrés López-Cortés, Santiago Guerrero
PURPOSE: Ethnic diversity in cancer research is crucial as race/ethnicity influences cancer incidence, survival, drug response, molecular pathways, and epigenetic phenomena. In 2018, we began a project to examine racial/ethnic diversity in cancer research, with a commitment to review these disparities every 4 years. This report is our second assessment, detailing the present state of racial/ethnic diversity in cancer genomics and clinical trials. METHODS: To study racial/ethnic inclusion in cancer genomics, we extracted ethnic records from all data sets available at cBioPortal (n = 125,128 patients) and cancer-related genome-wide association studies (n = 28,011,282 patients) between 2018 and 2022...
April 2024: JCO Precision Oncology
keyword
keyword
13909
3
4
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.